GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genetic Signatures Ltd (ASX:GSS) » Definitions » Price-to-Owner-Earnings

Genetic Signatures (ASX:GSS) Price-to-Owner-Earnings : (As of Jun. 04, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Genetic Signatures Price-to-Owner-Earnings?

As of today (2024-06-04), Genetic Signatures's share price is A$0.73. Genetic Signatures does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Genetic Signatures's Price-to-Owner-Earnings or its related term are showing as below:

During the past 9 years, the highest Price-to-Owner-Earnings of Genetic Signatures was 97.13. The lowest was 18.45. And the median was 50.06.


ASX:GSS's Price-to-Owner-Earnings is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 25.45
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-04), Genetic Signatures's share price is A$0.73. Genetic Signatures's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.13. Therefore, Genetic Signatures's PE Ratio for today is At Loss.

As of today (2024-06-04), Genetic Signatures's share price is A$0.73. Genetic Signatures's EPS without NRI for the trailing twelve months (TTM) ended in was A$-0.13. Therefore, Genetic Signatures's PE Ratio without NRI for today is At Loss.

During the past 9 years, Genetic Signatures's highest PE Ratio without NRI was 145.70. The lowest was 0.00. And the median was 70.44.


Genetic Signatures Price-to-Owner-Earnings Historical Data

The historical data trend for Genetic Signatures's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genetic Signatures Price-to-Owner-Earnings Chart

Genetic Signatures Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only - - 59.69 41.96 -

Genetic Signatures Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 41.96 - - -

Competitive Comparison of Genetic Signatures's Price-to-Owner-Earnings

For the Diagnostics & Research subindustry, Genetic Signatures's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genetic Signatures's Price-to-Owner-Earnings Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Genetic Signatures's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Genetic Signatures's Price-to-Owner-Earnings falls into.



Genetic Signatures Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Genetic Signatures's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.73/-0.10
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genetic Signatures  (ASX:GSS) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Genetic Signatures Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Genetic Signatures's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Genetic Signatures (ASX:GSS) Business Description

Traded in Other Exchanges
N/A
Address
7 Eliza Street, Newtown, Sydney, NSW, AUS, 2042
Genetic Signatures Ltd proprietary PCR solutions and automated workflows routinely screen for multiple infectious diseases in a single test. Rapid and accurate results facilitate improved patient management and healthcare outcomes. GSS continues to expand its global reach with direct representation in Australia, Europe, and the United States, and growing distribution partnerships. The company operates under one business segment which is the research and commercialisation of identifying individual genetic signatures to diagnose diseases and disabilities.